tapebrief
AMCR · Q2 2026

AMCR · Q3 2026 Earnings

Bearish

Amcor

Reported May 6, 2026

30-second summary

Amcor lowered FY26 adjusted EPS guidance to $3.98–4.03 (from $4.00–4.15, midpoint −2.9%) and slashed FY26 free cash flow guidance to $1.5–1.6B (from $1.8–1.9B, midpoint −16.7%), pinning the FCF cut on elevated inventory held at higher cost to mitigate Middle East supply disruption. Q3 adjusted EPS of $0.96 landed at the upper end of the $0.90–1.00 guide and Berry synergies of $77M came in at the top of the $70–80M range, but the FY26 setup management built over Q1-Q2 — synergy floor lifted, macro de-risked, bridge held — has now broken on the cash side. The synergy floor was raised to $270M (from "at least $260M"), which is the only constructive change in the print and is overshadowed by the magnitude of the FCF reduction.

Headline numbers

EPS

Q3 FY2026

$0.96

Revenue

Q3 FY2026

$5.91B

+77.0% YoY

Gross margin

Q3 FY2026

20.1%

Free cash flow

Q3 FY2026

$-0.04B

Operating margin

Q3 FY2026

7.8%

Key financials

Q3 FY2026
MetricQ3 FY2026YoYQ2 FY2026QoQ
Revenue$5.91B+77.0%$5.45B+8.5%
EPS$0.96—$0.86+11.6%
Gross margin20.1%—19.1%+100bps
Operating margin7.8%—6.1%+170bps
Free cash flow$-0.04B—$0.29B-113.5%

Guidance

Full-year EPS and Free Cash Flow guidance lowered materially; FCF cut 16.7% on higher inventory costs, while synergy target modestly exceeded.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted EPS
FY 2026
$4.00 to $4.15$3.98 to $4.03−$0.12 at midpoint (−2.9% vs prior midpoint $4.075)Lowered
Free Cash Flow
FY 2026
$1.8 billion to $1.9 billion$1.5 billion to $1.6 billion−$0.3 billion at midpoint (−16.7% vs prior midpoint $1.85B)Lowered
Berry Acquisition Synergies (pre-tax)
FY 2026
at least $260 million$270 million+$10 millionRaised

Segment KPIs

Q3 FY2026
SegmentQ3 FY2026YoY
Global Flexible Packaging Solutions$3.25B+35.0%
Global Rigid Packaging Solutions$2.664B+187.0%

Other KPIs

Q3 FY2026
SegmentQ3 FY2026
Adjusted EBITDA$892 million
Adjusted EBITDA Margin15.1%
Adjusted EBIT$687 million
Adjusted EBIT Margin11.6%
Acquisition Synergies (Q3)$77 million
Organic Volume Growth-1.0%
Price/Mix Impact1.0%
Net Debt$14,266 million

Management tone

Q4-25 stabilization-and-pruning → Q1-26 forward-leaning execution → Q2-26 quiet retrenchment → Q3-26 explicit cut.

The de-risking language built up in Q1 has fully unwound. Two quarters ago management asserted FY26 EPS growth was "not dependent on improvements in the macroeconomic environment or in customer or consumer demand." Last quarter that sentence disappeared. This quarter the FY26 EPS guide was cut and the FCF guide was reduced 16.7% — and the framing has shifted from "controllable execution" to working capital and supply-continuity choices. PK in Q&A: "Continuity of supply is a critical priority for our customers, and to meet that need, we have made choices about working capital management, primarily inventory, through the fourth quarter." The Q1 promise that the bridge would hold regardless of macro is now demonstrably broken.

The Middle East conflict became a structural mitigation regime, not a discrete event. Last quarter Middle East exposure was not a featured topic; this quarter it anchors the FCF cut. PK described the response as ongoing rather than episodic: "It's not a one-off. It's not a destination here. It's a journey." That language is materially different from the controllable-synergy narrative of Q1-Q2 and signals management expects sustained inventory elevation and customer pricing negotiations through at least Q4.

The synergy floor moved up — but in a context where it no longer carries the bridge. Q1 lifted the synergy framing from "$260M" to "at least $260M"; Q2 held that floor flat; Q3 explicitly raises to $270M. In isolation this is a positive operational signal. In context, raising synergies $10M while cutting EPS $0.12 at midpoint tells investors that the EPS guide was being held in Q1-Q2 partly on the implicit assumption synergies would absorb operational drag — and that drag has now exceeded the synergy upside.

Volume framing oscillated and is now slightly worse than Q2. Q2 quantified core volumes down 1.5%; this quarter management acknowledged "volumes have been down 2% versus an original guidance assuming more flattish." The −0.5pp drift is small in isolation but matters because it is the second consecutive quarter where the volume reality has moved further from the FY26 base case.

Recurring themes management leaned on this quarter:

Middle East supply chain mitigation through inventory elevation and customer collaborationSynergy acceleration exceeding initial year-one targets despite inflationary headwindsPortfolio optimization progressing with $500M in divestitures completed or agreedWorking capital and free cash flow pressure from elevated inventory holdings at higher costsPersistent but moderating volume declines in developed markets offset by emerging market growthPass-through pricing mechanisms and customer relationships offsetting input cost inflation

Risks management surfaced:

Middle East conflict creating supply chain disruption requiring sustained inventory elevationConsumer already stretched by prior inflation; additional resin cost inflation expected to flow through over timeVolume declines in developed markets (North America low single digits down, Europe similar to prior quarter)Input cost inflation significantly exceeding historical norms requiring accelerated price actionsWinter storm impact of $25M in Q3; additional supply chain volatility in H2Uncertainty around timing and magnitude of resin cost pass-through to consumers

Q&A highlights

Hillary Coconato · Deutsche Bank

Can you provide recent examples of growth synergies where the combined AMCO and BERI product portfolio won new contracts?

Management highlighted $100 million in annualized synergy deals closed year-to-date (vs. $280 million expected over three years), with $110 million now achieved. They provided a specific example of a Global Pharma customer developing GLP-1 oral solid dose drugs requiring different packaging formats for Europe (blister) and North America (rigid container), which the combined company was uniquely positioned to serve.

$100 million annualized synergy deals closed to date$280 million total growth synergies expected over three years$110 million synergies achieved year-to-dateCouple of million bottom-line impact in Q3

Gabe Hyde · Wells Fargo Securities

Can you comment on healthcare and nutrition as focus areas, particularly weakness in healthcare and expected improvement beginning mid-2026?

Management clarified that five of six focus categories were flat to low-to-mid single digits up, with healthcare showing slight volume declines offset by positive mix. They attributed healthcare weakness to U.S. winter storm impacts on production/customer pull-through and weaker cold/flu season. Nutrition weakness was driven by discretionary categories and fresh/frozen food, not the focus nutrition categories. Management expressed confidence in healthcare as a market and highlighted recent wins with pharma customers, a generics partnership on sustainability, and a new Malaysia coding facility opened in April.

Six focus categories flat while overall core business down 1.5%Five of six focus categories flat or low-to-mid single digits upHealthcare volumes slightly down with positive mix offsettingU.S. winter storm impacted production and customer pull-through

Answers to last quarter's watch list

Whether the withdrawn FY26 disclosures (CapEx $850–900M, interest $570–600M, tax 19–21%) are reissued or further suppressed in Q3. Not reissued. The three line items remain absent from the press release framework. With EPS and FCF now also cut, the silent withdrawal that looked like a forward-commitment recalibration in Q2 looks more like a deliberate reduction of falsifiable disclosure ahead of a deteriorating outlook.
Resolved negatively
Q3 adjusted EPS landing at or above $0.90–1.00 with $70–80M synergies. Resolved cleanly: EPS $0.96 (upper half), synergies $77M (top of range). YTD synergies $170M against the new $270M target leaves $100M required in Q4, slightly above the Q3 run-rate but achievable.
Resolved positively
Non-core EBIT margin trajectory in North American beverage. Management said Q3 profitability improved sequentially driven by volume and margin recovery initiatives, with margins "in line with expectations" and further sequential improvement expected in Q4. No specific Q3 margin figure was disclosed, so the bridge from ~3% Q2 to the 7–9% H2 target cannot be verified from the print.
Continue monitoring
Explicit divestiture announcement. Multiple divestiture agreements were announced over the last three months, with management quantifying $500M in divestitures completed or agreed against the ~$2.5B non-core pool. This is the most concrete portfolio action since the assets were flagged at deal close.
Resolved positively
Flex segment operating leverage ex-synergies. Not directly addressed in disclosed Q&A. Flex revenue $3.25B (+35% YoY combined-entity) with no segment-level synergy split or ex-synergy EBIT walk provided in the press release.
Continue monitoring

What to watch into next quarter

FY26 free cash flow landing within or above the new $1.5–1.6B guide. A second downward revision would signal the inventory mitigation is structural rather than Q4-bounded, materially changing the deleveraging path beyond the now-acknowledged 3.4–3.5x year-end leverage.

Q4 synergy capture of ~$100M to hit the raised $270M FY26 floor. Q3's $77M was the largest quarterly figure to date; the Q4 step-up requires further acceleration. A miss would put the raised floor at risk in the same quarter it was lifted.

Whether the CapEx, interest, and tax FY26 line items return to disclosure. Three quarters of silent suppression now coincide with material guidance cuts on the two metrics that remain disclosed. Reissuance would be a credibility marker; continued absence raises the question of whether further line items are being insulated from forward commitment.

Volume trajectory in the core portfolio. Core down 1.5% in Q2, down 2% versus original assumption in Q3. A third consecutive quarter of deterioration would put the FY27 organic growth thesis under pressure once the synergy tailwind moderates.

Explicit disclosure of North American beverage Q3 EBIT margin and divestiture proceeds from the $500M of agreed sales. The bridge math from H1 ~5% margin to H2 7–9% requires Q3-Q4 in the 7–9% band; without disclosure the bridge cannot be audited.

Sources

  1. Amcor Q3 FY2026 press release (SEC filing): https://www.sec.gov/Archives/edgar/data/1748790/000174879026000014/exhibit991q32026.htm
  2. Amcor Q3 FY2026 earnings call Q&A (analyst exchanges with Coconato, Hyde, and Anthony).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.